Saturday 17 October 2026
Export LUCY’s income statement to Excel — free account
Innovative Eyewear, Inc.
LUCY Healthcare Medical Instruments & Supplies
Innovative Eyewear, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 million, up 62.7% from fiscal 2024. In the quarter to June 2026, revenue grew 74.5%, EPS grew 60.6%, free cash flow grew 9.61% and total debt fell 92.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.79
0.05
−5.95%
Follow LUCY
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 4 | 4 | 5 | 4 |
Altman Z-Score |
— | — | 2.14 | (1.61) | 0.97 | (3.75) |
P/S ratio |
48.32 | 48.32 | 12.37 | 4.79 | 4.50 | 1.50 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(65.85) | (43.85) | (3.71) | (2.19) | 4.91 | (1.73) |
P/Operating CF |
(70.65) | (70.65) | (7.30) | (4.11) | (3.79) | (2.96) |
Beneish M-Score |
— | — | — | — | (3.77) | (2.44) |
P/B ratio |
0.00 | 0.00 | 2.03 | 0.99 | 0.81 | 0.44 |
Price to Tangible BV |
0.00 | 0.00 | 2.10 | 1.05 | 0.85 | 0.47 |
EV/Sales |
50.90 | 50.90 | 7.02 | 1.12 | (0.06) | (0.91) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.29 |
EV/Operating CF |
(18.70) | (18.70) | (1.44) | (0.22) | 0.02 | 0.33 |
EV/FCF |
(17.27) | (17.27) | (1.35) | (0.21) | 0.01 | 0.32 |
Quick Ratio |
0.04 | 0.20 | 6.17 | 7.01 | 10.35 | 6.36 |
Current Ratio |
0.19 | 1.04 | 7.07 | 8.99 | 12.52 | 9.03 |
Net Debt/EBITDA |
(0.88) | (0.07) | 0.64 | 0.63 | 0.97 | 0.78 |
Debt/Assets |
284.12% | 35.06% | 1.31% | 0.00% | 0.00% | 0.28% |
Debt/Equity |
(1.08) | 1.39 | 0.02 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 1.33 | 0.24 | 0.21 | 0.20 | 0.27 |
Operating CF/Net income |
0.05 | 0.37 | 0.57 | 0.87 | 0.87 | 0.96 |
Capex/Depreciation |
(0.52) | (15.39) | (6.75) | (2.92) | (3.16) | (1.85) |
Interest Coverage |
(153.06) | (81.35) | (53.01) | (2,285.17) | — | — |
| 0.00% | 1,868.41% | (268.52%) | (139.06%) | (106.00%) | (83.60%) | |
| 0.00% | (626.77%) | (206.08%) | (122.17%) | (96.74%) | (75.99%) | |
ROIC |
(2,702.33%) | (480.61%) | (704.56%) | (337.01%) | (315.25%) | (205.50%) |
Return on Tangible Assets |
123.09% | (6,787.66%) | (151.10%) | (129.46%) | (90.22%) | (89.82%) |
Average Days of Receivables |
0.00 | 22.93 | 61.02 | 29.52 | 24.07 | 19.50 |
Research and Development Expense of Revenue |
64.74% | 12.49% | 79.52% | 57.46% | 50.07% | 27.25% |
Selling, General and Administrative Expense of Revenue |
822.46% | 457.09% | 735.94% | 514.88% | 438.74% | 307.96% |
Intangible Assets out of Total Assets |
0.33 | 0.11 | 0.03 | 0.05 | 0.05 | 0.06 |
Share Based Compensation of Revenue |
143.16% | 193.27% | 223.39% | 81.28% | 47.35% | 27.73% |
Graham Net Nets |
(0.05) | (0.05) | 0.44 | 0.90 | 1.15 | 2.09 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(11.86%) | (11.86%) | (69.90%) | (139.29%) | (127.44%) | (204.00%) |
Free Cash Flow Yield |
(6.10%) | (6.10%) | (42.20%) | (109.04%) | (97.98%) | (189.86%) |
Revenue per Share |
0.39 | 2.63 | 2.02 | 1.88 | 1.09 | 0.67 |
Operating CF per Share |
(0.27) | (4.63) | (9.88) | (9.41) | (4.51) | (1.82) |
Capex per Share |
(0.40) | (0.45) | (0.67) | (0.41) | (0.32) | (0.06) |
Free Cash Flow per Share |
(0.67) | (5.08) | (10.55) | (9.81) | (4.82) | (1.88) |
Cash per Share |
0.18 | 0.30 | 11.00 | 6.99 | 5.03 | 1.63 |
Shareholders Equity per Share |
(3.75) | 0.79 | 12.33 | 9.07 | 6.08 | 2.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(3.75) | 0.79 | 12.33 | 9.07 | 6.08 | 2.27 |
Free Cash Flow |
(0.10) | (1.33) | (3.44) | (6.02) | (7.21) | (7.52) |
Working Capital |
(0.62) | 0.03 | 3.64 | 4.99 | 8.50 | 8.39 |
Capital Expenditures |
(0.06) | (0.12) | (0.22) | (0.25) | (0.47) | (0.25) |
Net Current Asset Value |
(0.62) | 0.03 | 3.58 | 4.96 | 8.50 | 8.36 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.29 |
Capex to Sales |
1.04 | 0.17 | 0.33 | 0.22 | 0.29 | 0.09 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
0.00 | 0.38 | 0.27 | 0.55 | 1.39 | 2.19 |
Cash ROIC |
(138.49%) | (231.29%) | (44.87%) | (61.10%) | (43.39%) | (48.22%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 8.59 | 11.33 | 16.27 | 21.29 |
Accounts Payable Turnover |
0.00 | 4.96 | 3.23 | 2.97 | 2.23 | 2.50 |
Inventory Turnover |
0.00 | 2.52 | 2.26 | 2.21 | 1.35 | 1.22 |
Average Days of Payables |
252.50 | 112.45 | 140.53 | 167.03 | 177.92 | 171.75 |
Days of Inventory on Hand |
441.14 | 228.93 | 149.09 | 245.90 | 322.65 | 380.58 |
Average Receivables |
— | — | 0.08 | 0.10 | 0.10 | 0.13 |
Average Payables |
— | 0.11 | 0.22 | 0.43 | 0.64 | 0.84 |
Average Inventory |
— | 0.22 | 0.32 | 0.57 | 1.06 | 1.72 |
Average Assets |
— | 0.52 | 2.76 | 5.45 | 8.03 | 9.99 |
Average Common Equity |
— | (0.17) | 2.12 | 4.79 | 7.33 | 9.08 |
Columns are period end dates